Related Experiment Video

Updated: Apr 11, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.9K

The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?

S Morteza Seyed Jafari1, Gemma Caro2, Shari R Lipner3

  • 1Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. morteza.jafari@insel.ch.

American Journal of Clinical Dermatology
|April 9, 2026
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show mixed effects on hair health, with some studies reporting benefits and others suggesting links to hair loss conditions like telogen effluvium. Further research is needed to clarify their impact on hair biology.

Area of Science:

  • Endocrinology
  • Dermatology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established treatments for type II diabetes and obesity.
  • Emerging evidence suggests GLP-1RAs may influence various physiological processes beyond metabolic regulation.
  • The relationship between GLP-1RA use and hair health remains a subject of ongoing investigation and debate.

Purpose of the Study:

  • To review and synthesize current scientific literature on the association between GLP-1RAs and hair-related conditions.
  • To evaluate the conflicting reports regarding GLP-1RA effects on different types of alopecia.
  • To identify knowledge gaps and propose future research directions.

Main Methods:

  • Narrative review of existing studies.
  • Analysis of reported cases and clinical observations linking GLP-1RAs to hair changes.
  • Synthesis of evidence concerning androgenetic alopecia, cicatricial alopecia, and telogen effluvium.

Main Results:

  • Some studies indicate potential benefits, such as hair regrowth in androgenetic alopecia and reduced inflammation in cicatricial alopecia.
  • A significant number of reports suggest a correlation between GLP-1RA use and the development of telogen effluvium.
  • The current evidence is heterogeneous, presenting a complex picture of GLP-1RA effects on hair.

Conclusions:

  • Clinical evaluation and monitoring of patients on GLP-1RAs for hair changes are crucial.
  • Further prospective, controlled studies are required to elucidate the precise role of GLP-1RAs in hair follicle biology.
  • Understanding these effects is vital for safe prescribing and to prevent unnecessary treatment discontinuation.

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.9K
Roux-en-Y Gastric Bypass Operation in Rats07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
901
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
980
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K